|
Budesonide
|
16,17-(butylidenebis(oxy))-11,21-dihydroxy-,
(11-β,16-α)-pregna-1,4-diene-3,20-dione |
CAS number
51333-22-3 |
ATC codes
A07EA06, D07AC09, R01AD05, R03BA02 |
| Chemical formula |
C25H34O6 |
| Molecular weight |
430.5376 |
| Bioavailability |
6% |
| Metabolism |
Hepatic |
| Elimination half-life |
2-3 Hours |
| Excretion |
Renal, Faecal |
| Pregnancy category |
C (USA) |
| Legal status |
? |
| Routes of administration |
Nasal, tracheal, rectal |
Budesonide is a corticosteroid for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. Additionally, it is used for inflammatory bowel disease. It is marketed by AstraZeneca as a nasal inhalation with the brand name Rhinocort, as an oral inhalation with the brand name Pulmicort, and as an enema and a modified-release capsule with the brand name Entocort. It is also sold in combined with formoterol (Oxis) in a single inhaler, with the brand name Symbicort.
Budesonide has a high first pass metabolism. It has efficacy in the terminal ileum and the right colon. It has a lower incidence of systemic manifestations than similar medications.
|
